Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Feb 1;183(2):115-123.
doi: 10.1001/jamainternmed.2022.5909.

Effect of COVID-19 Vaccine Messaging Platforms in Emergency Departments on Vaccine Acceptance and Uptake: A Cluster Randomized Clinical Trial

Collaborators, Affiliations
Randomized Controlled Trial

Effect of COVID-19 Vaccine Messaging Platforms in Emergency Departments on Vaccine Acceptance and Uptake: A Cluster Randomized Clinical Trial

Robert M Rodriguez et al. JAMA Intern Med. .

Abstract

Importance: Large segments of the US population's primary health care access occurs in emergency departments (EDs). These groups have disproportionately high COVID-19 vaccine hesitancy and lower vaccine uptake.

Objective: To determine whether provision of COVID-19 vaccine messaging platforms in EDs increases COVID-19 vaccine acceptance and uptake in unvaccinated patients.

Design, setting, and participants: This prospective cluster randomized clinical trial was conducted at 7 hospital EDs in 4 US cities from December 6, 2021, to July 28, 2022. Noncritically ill adult patients who had not previously received COVID-19 vaccines were enrolled.

Interventions: A 3-pronged COVID-19 vaccine messaging platform (an English- or Spanish-language 4-minute video; a 1-page informational flyer; and a brief, scripted message from an ED physician or nurse) was delivered during patient waiting times.

Main outcomes and measures: The 2 primary outcomes were (1) COVID-19 vaccine acceptance, assessed by survey responses in the ED, and (2) receipt of a COVID-19 vaccine within 30 days, ascertained by ED confirmation of vaccination, electronic health record review, and telephone follow-up.

Results: Of the 496 participants enrolled (221 during intervention weeks and 275 during control weeks), the median (IQR) age was 39 (30-54) years, 205 (41.3%) were female, 193 (38.9%) were African American, 97 (19.6%) were Latinx, and 218 (44.0%) lacked primary care physicians. More intervention group participants, compared with control participants, stated that they would accept the vaccine in the ED (57 [25.8%] vs 33 [12.0%]; adjusted difference, 11.9 [95% CI, 4.5-19.3] percentage points; number needed to treat [NNT], 8 [95% CI, 5-22]). More intervention group participants than control participants received a COVID-19 vaccine within 30 days of their ED visit (44 [20.0%] vs 24 [8.7%]; adjusted difference, 7.9 [95% CI, 1.7-14.1] percentage points; NNT, 13 [95% CI, 7-60]). The intervention group had greater outcome effect sizes than the control group in participants who lacked a primary care physician (acceptance, 38 of 101 [37.6%] vs 16 of 117 [13.7%] [P for interaction = .004]; uptake, 31 of 101 [30.7%] vs 11 of 117 [9.4%] [P for interaction = .006]), as well as in Latinx persons (acceptance, 23 of 52 [44.2%] vs 5 of 48 [10.4%] [P for interaction = .004]; uptake, 22 of 52 [42.3%] vs 4 of 48 [8.3%] [P for interaction < .001]).

Conclusions and relevance: Results of this cluster randomized clinical trial showed that with low NNT, implementation of COVID-19 vaccine messaging platforms in EDs leads to greater vaccine acceptance and uptake in unvaccinated ED patients. Broad implementation in EDs could lead to greater COVID-19 vaccine delivery to underserved populations whose primary health care access occurs in EDs.

Trial registration: ClinicalTrials.gov Identifier: NCT05142332.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Chang reported grants from Abbott outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. CONSORT Flow Diagram
aParticipants were withdrawn if they became too ill, left the emergency department (ED) prior to completion of study procedures, or asked to be withdrawn.

References

    1. COVID data tracker. Centers for Disease Control and Prevention . Accessed November 18, 2022. https://covid.cdc.gov/covid-data-tracker/#trends_totaldeaths_select_00
    1. Amin K, Ortaliza J, Cox C, Michaud J, Kates J. COVID-19 mortality preventable by vaccines. Petersen-KFF Health Systems Tracker . April 21, 2022. Accessed November 18, 2022. https://www.healthsystemtracker.org/brief/covid19-and-other-leading-caus...
    1. Steele MK, Couture A, Reed C, et al. . Estimated number of COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in the US, December 2020 to September 2021. JAMA Netw Open. 2022;5(7):e2220385. doi:10.1001/jamanetworkopen.2022.20385 - DOI - PMC - PubMed
    1. KFF COVID-19 vaccine monitor dashboard. Kaiser Family Foundation . Accessed November 18, 2022. https://www.kff.org/coronavirus-covid-19/dashboard/kff-covid-19-vaccine-...
    1. Szilagyi PG, Thomas K, Shah MD, et al. . National trends in the US public’s likelihood of getting a COVID-19 vaccine—April 1 to December 8, 2020. JAMA. 2020;325(4):396-398. doi:10.1001/jama.2020.26419 - DOI - PMC - PubMed

Publication types

Substances

Associated data